Corbus Pharmaceuticals Holdings Free Cash Flow (FCF) History (CRBP)
Corbus Pharmaceuticals Holdings reported −$64.5M in free cash flow for fiscal 2025, a decrease of $22.7M from the previous fiscal year.
View full Corbus Pharmaceuticals Holdings company overviewCorbus Pharmaceuticals Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$64.5M | −$22.7M | — | — |
| 2024 | 2024-12-31 | −$41.8M | −$5.7M | — | — |
| 2023 | 2023-12-31 | −$36.1M | $1.5M | — | — |
| 2022 | 2022-12-31 | −$37.6M | $10.7M | — | — |
| 2021 | 2021-12-31 | −$48.2M | $51.9M | — | −5470.98% |
| 2020 | 2020-12-31 | −$100.2M | −$51.7M | — | −2544.18% |
| 2019 | 2019-12-31 | −$48.5M | −$16.1M | — | −134.09% |
| 2018 | 2018-12-31 | −$32.4M | −$3.9M | — | −671.21% |
| 2017 | 2017-12-31 | −$28.5M | −$14.6M | — | −1168.11% |
| 2016 | 2016-12-31 | −$13.9M | −$9.2M | — | −728.48% |
| 2015 | 2015-12-31 | −$4.7M | −$2.3M | — | −730.88% |
| 2014 | 2014-12-31 | −$2.4M | — | — | — |
Corbus Pharmaceuticals Holdings quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$29.6M | −$23.6M | — | — |
| Q1 2026 | 2026-03-31 | −$25.6M | −$18.4M | — | — |
| Q2 2025 | 2025-06-30 | −$16.6M | −$8.8M | — | — |
| Q1 2025 | 2025-03-31 | −$16.4M | −$1.3M | — | — |
| Q4 2023 | 2023-12-31 | −$6.0M | $1.4M | — | — |
| Q3 2023 | 2023-09-30 | −$7.2M | $69,046 | — | — |
| Q2 2023 | 2023-06-30 | −$7.8M | $4.4M | — | — |
| Q1 2023 | 2023-03-31 | −$15.1M | −$4.5M | — | — |
| Q4 2022 | 2022-12-31 | −$7.5M | $10.8M | — | — |
| Q3 2022 | 2022-09-30 | −$7.2M | $20.1M | — | — |
| Q2 2022 | 2022-06-30 | −$12.2M | $14.4M | — | — |
| Q1 2022 | 2022-03-31 | −$10.6M | $17.4M | — | — |
| Q4 2020 | 2020-12-31 | −$18.3M | $5.6M | — | −2776.71% |
| Q3 2020 | 2020-09-30 | −$27.3M | −$9.0M | — | −2219.20% |
| Q2 2020 | 2020-06-30 | −$26.6M | −$10.0M | — | −9297.60% |
| Q1 2020 | 2020-03-31 | −$28.1M | −$38.3M | — | −1592.73% |
| Q4 2019 | 2019-12-31 | −$23.9M | −$9.5M | — | −926.88% |
| Q3 2019 | 2019-09-30 | −$18.3M | −$9.3M | — | −705.89% |
| Q2 2019 | 2019-06-30 | −$16.6M | −$10.3M | — | −56.96% |
| Q1 2019 | 2019-03-31 | $10.2M | $13.1M | — | +543.29% |
| Q4 2018 | 2018-12-31 | −$14.3M | −$4.6M | — | −742.70% |
| Q3 2018 | 2018-09-30 | −$9.0M | −$2.6M | — | −820.69% |
| Q2 2018 | 2018-06-30 | −$6.2M | −$475,433 | — | −730.02% |
| Q1 2018 | 2018-03-31 | −$2.9M | $3.8M | — | −301.86% |
| Q4 2017 | 2017-12-31 | −$9.7M | −$4.1M | — | — |
| Q3 2017 | 2017-09-30 | −$6.4M | −$3.3M | — | −800.85% |
| Q2 2017 | 2017-06-30 | −$5.8M | −$3.1M | — | −1643.80% |
| Q1 2017 | 2017-03-31 | −$6.7M | −$4.1M | — | −516.06% |
| Q4 2016 | 2016-12-31 | −$5.6M | −$4.6M | — | −1483.92% |
| Q3 2016 | 2016-09-30 | −$3.1M | −$632,744 | — | −420.29% |
| Q2 2016 | 2016-06-30 | −$2.6M | −$2.7M | — | −667.79% |
| Q1 2016 | 2016-03-31 | −$2.6M | −$1.3M | — | −650.61% |
| Q4 2015 | 2015-12-31 | −$974,023 | −$339,270 | — | −267.37% |
| Q3 2015 | 2015-09-30 | −$2.5M | — | — | −1459.71% |
| Q2 2015 | 2015-06-30 | $4,975 | — | — | +4.38% |
| Q1 2015 | 2015-03-31 | −$1.3M | — | — | — |
| Q3 2014 | 2014-09-30 | −$634,753 | — | — | — |
Corbus Pharmaceuticals Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$100.2M to −$64.5M, a net increase of $35.7M. Corbus Pharmaceuticals Holdings's latest reported quarter, Q2 2026, generated −$29.6M in free cash flow, a decrease of $23.6M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Corbus Pharmaceuticals Holdings filings at SEC.gov ↗